Does additional HIPEC help after CRS in peritoneal disseminated gastric cancer?

Abstract

The incidence of synchronous or metachronous peritoneal metastases (PM) in patients with locally advanced gastric cancer is high, and associated with a poor prognosis. The recommended therapeutic option for these patients is systemic chemotherapy and leads to a median of 7-8 months. However, new approaches like cytoreductive surgery and hyperthermic intraperitoneal chemotherapy might help to improve the median survival in selected patients.

Keywords

• gastric adenocarcinoma
• hyperthermic intraperitoneal chemotherapy (hipec)
• peritoneal metastasis
• peritoneal carcinomatosis
• gastripec trial